2-(3,4-dihydroxy-benzylidene)-benzo[b]thiophen-3-one | 24388-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(3,4-dihydroxy-benzylidene)-benzo[b]thiophen-3-one
• 英文别名: 2-(3,4-Dihydroxy-benzyliden)-benzo[b]thiophen-3-on；(2E)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzothiophen-3-one
• CAS: 24388-08-7
• 化学式: C₁₅H₁₀O₃S
• 分子量: 270.309
• InChiKey: WZFCZVJGQHEBMO-RIYZIHGNSA-N

物化性质

• 沸点：
  511.9±50.0 °C(Predicted)
• 密度：
  1.508±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-羟基苯并噻吩 、 3,4-二羟基苯甲醛 在 盐酸 、 溶剂黄146 作用下， 生成 2-(3,4-dihydroxy-benzylidene)-benzo[b]thiophen-3-one
  参考文献：
  名称：

  Friedlaender, Monatshefte fur Chemie, 1909, vol. 30, p. 353

  摘要：

  DOI：

文献信息

• Sphingosine kinase inhibitors
  申请人：The Pennsylvania State University Research Foundation

  公开号：US20040034075A1

  公开（公告）日：2004-02-19

  The invention relates to compounds, compositions and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy.

  本发明涉及用于抑制鞘氨醇激酶和治疗或预防过度增殖性疾病、自身免疫性疾病、炎症性疾病或过敏症的化合物、组合物和方法。
• Method of Treating or Sepsis
  申请人：Hauser Carl J.

  公开号：US20080280866A1

  公开（公告）日：2008-11-13

  Provided is a method of treating trauma or sepsis comprising: administering an effective amount of one or both of a SOC channel-selective inhibitor or a SphK inhibitor to an animal at risk of inflammation-mediated organ damage from trauma or sepsis.
• Treatment Of Ischemia-Reperfusion Injury
  申请人：Smith Charles D.

  公开号：US20120122870A1

  公开（公告）日：2012-05-17

  Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.
• [EN] METHOD OF TREATING TRAUMA OR SEPSIS<br/>[FR] PROCEDE POUR TRAITER UN TRAUMA OU UNE SEPSIE
  申请人：HAUSER CARL J

  公开号：WO2006019586A2

  公开（公告）日：2006-02-23

  Provided is a method of treating trauma or sepsis comprising: administering an effective amount of one or both of a SOC channel-selective inhibitor or a SphK inhibitor to an animal at risk of inflammation-mediated organ damage from trauma or sepsis.
• [EN] TREATMENT OF ISCHEMIA-REPERFUSION INJURY<br/>[FR] TRAITEMENT D'UNE LÉSION D'ISCHÉMIE-REPERFUSION
  申请人：APOGEE BIOTECHNOLOGY CORP

  公开号：WO2010129954A1

  公开（公告）日：2010-11-11

  Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR -induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.